First Sublingual Ketamine Drug for Treatment of Acute Pain to be Evaluated in End-of-Phase 2 Meeting with FDA

[In The News]

Racemic sublingual ketamine, Wafermine, is the first sublingual ketamine drug seeking FDA approval for the treatment of moderate to severe acute pain Wafermine is a Phase 2-ready drug for treatment resistant depression SINGAPORE, May 21, 2019 /PRNewswire/ -- iX Biopharma Ltd (SGX:42C)...

View the full article